ArticleRMD open2021
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.
Article in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis.Nature reviews. Rheumatology · 2023Guideline
- Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.RMD open · 2025Trial
- Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.Immunity, inflammation and disease · 2026Article
- Impact of sex and HLA-B27 positivity on clinical characteristics and patient-reported outcomes in a cohort of Egyptian axial spondyloarthritis patients.BMC musculoskeletal disorders · 2026Article
- From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis.Arthritis care & research · 2026Review
- Impact of comorbidities and extra-musculoskeletal manifestations on radiographic progression in ankylosing spondylitis.Rheumatology (Oxford, England) · 2026Article
- Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network.RMD open · 2026Article
- Cycling or Swapping in Spondyloarthritis? Current Knowledge.Mediterranean journal of rheumatology · 2026Review
- Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.EULAR rheumatology open · 2026Article
- Spondyloarthritis in Latin America: a difficult-to-diagnose challenge.Therapeutic advances in musculoskeletal disease · 2026Review
- Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).Therapeutic advances in musculoskeletal disease · 2026Review
- Clinical characteristics of peripheral joint disease in axial and peripheral spondyloarthritis: findings from a multicentre cross-sectional study.Rheumatology international · 2025Article
- Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study.BMC rheumatology · 2025Article
- Article
- Uveitis in Longstanding Axial Spondyloarthritis and Its Association with Biologic Therapy Initiation: Data from the REGISPON-3 Cohort.Journal of clinical medicine · 2025Article
- Global epidemiology of spondyloarthritis.Nature reviews. Rheumatology · 2025Review
- Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis.Clinical rheumatology · 2025Article
- Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- DEUS Enthesitis Index (DEI): a new tool integrating ultrasound and clinical examination for enthesitis assessment in spondyloarthritis.RMD open · 2025Observational
- HLA-B5 prevalence in patients with spondyloarthritis and impact on disease phenotype: a multicentric case-control study.Rheumatology (Oxford, England) · 2025Observational
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 25 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo characterise peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world.
methodsCross-sectional study with 24 participating countries. Patients with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or PsA according to their rheumatologist were included. The investigators were asked which diagnosis out of a list of six (axSpA, PsA, pSpA, inflammatory bowel disease-associated SpA, reactive arthritis or juvenile SpA (Juv-SpA)) fitted the patient best. Peripheral manifestations (ie, peripheral joint disease, enthesitis, dactylitis and root joint disease), their localisation and treatments were evaluated.
resultsA total of 4465 patients were included (61% men, mean age 44.5 years) from four geographic areas: Latin America (n=538), Europe plus North America (n=1677), Asia (n=975) and the Middle East plus North Africa (n=1275). Of those, 78% had ever suffered from at least one peripheral musculoskeletal manifestation; 57% had peripheral joint disease, 44% had enthesitis and 15% had dactylitis. Latin American had far more often peripheral joint disease (80%) than patients from other areas. Patients with PsA had predominantly upper limb and small joint involvement (52%).Hip and shoulder involvement was found in 34% of patients. The prevalence of enthesitis ranged between 41% in patients with axSpA and 65% in patients with Juv-SpA. Dactylitis was most frequent among patients with PsA (37%).
conclusionThese results suggest that all peripheral features can be found in all subtypes of SpA, and that differences are quantitative rather than qualitative. In a high proportion of patients, axial and peripheral manifestations coincided. These findings reconfirm SpA clinical subtypes are descendants of the same underlying disease, called SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.